{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021973","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.651764+00:00","generated_at":"2026-06-15T00:50:44.231502+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Biopharma Q1 2023: Revenue $12.7M, cash $251.5M, runway into H2 2024","bullets":["Cash and investments $251.5M plus Vaxcyte shares valued at $25.0M; cash runway into second half of 2024.","Revenue of $12.7M for Q1 2023 up from $5.9M in Q1 2022, primarily from Astellas, Merck, BMS collaborations.","Total Q1 operating expenses $54.9M ($39.4M R&D, $15.5M G&A) vs $45.0M in Q1 2022.","Luvelta Phase 1 dose-expansion data to be oral presentation at ASCO 2023; REFRaME registration trial initiation in Q2 2023.","Leadership changes: Venkatesh Srinivasan promoted to CTOO; Trevor Hallam stepping down as President/CSO effective May 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021973","json":"https://secwatch.observer/filing/0000950170-23-021973.json","markdown":"https://secwatch.observer/filing/0000950170-23-021973.md","text":"https://secwatch.observer/filing/0000950170-23-021973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023021973/0000950170-23-021973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023021973/stro-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:50:44.231502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2283565af456f5a031e9a82fb689f9b487f6db1","claim":"SUTRO BIOPHARMA, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023021973/0000950170-23-021973-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}